FDA Approves NINTEDANIB ESYLATE — Macleods Pharmaceuticals Limited

Macleods Pharmaceuticals has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA219926) for oral nintedanib esylate, facilitating market entry for this competitor to a key oncology treatment. The launch is expected to bolster Macleods' presence in the global pharma sector by offering a cost-effective alternative in a high-demand therapeutic area.